Brief: Denali Therapeutics Announces New Interim Data From Phase 1/2 Study Of Dnl310
30/08/2023 13:43
Aug 30 (Reuters) - Denali Therapeutics Inc DNLI.O :
* DENALI THERAPEUTICS ANNOUNCES NEW INTERIM DATA FROM PHASE
1/2
STUDY OF DNL310 (ETV:IDS) IN MPS II (HUNTER SYNDROME) AT SSIEM
2023
* DENALI THERAPEUTICS INC - ADDITIONAL SAFETY DATA UP TO TWO
YEARS
OF TREATMENT CONTINUE TO DEMONSTRATE THAT DNL310 IS GENERALLY
WELL TOLERATED
* DENALI THERAPEUTICS INC - RECRUITMENT IN GLOBAL PHASE 2/3
COMPASS STUDY IS ONGOING
Source text for Eikon: ID:nGNX2rJJnH
Further company coverage: DNLI.O
Recent news on Denali Therapeutics
See all newsDenali Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Denali Therapeutics Q2 net loss widens as AVLAYAH launch costs rise
Biogen's Alzheimer's drug lowers toxic protein, but results were mixed
U.S. STOCKS ON THE MOVE-Sweetgreen, Dell Technologies, Peloton Interactive
U.S. STOCKS ON THE MOVE-IMAX, Novo Nordisk, PC makers